Aadi Bioscience Cuts 80% of R&D Staff Amid Fyarro Expansion Setbacks

Aadi Bioscience Layoffs:
Aadi Bioscience has announced a significant reduction in its research and development (R&D) workforce, cutting 80% of its staff.

Reason for Layoffs:
The layoffs are a result of the faltering expansion efforts of Fyarro, a drug used to treat malignant perivascular epithelioid cell tumors (PEComa).

Fyarro's Current Use:
Fyarro is currently approved for treating adults with metastatic or locally advanced, unresectable PEComa.

Phase 2 Trial Failure:
A mid-stage study intended to support expanded approval of Fyarro is on track to fail, leading to the halt of the study and the significant layoffs.

Impact on Aadi Bioscience:
The failure of Fyarro's expansion efforts and the subsequent layoffs indicate significant challenges for Aadi Bioscience in advancing its drug pipeline and maintaining its R&D capabilities.